24-NHL-40-AB (M22-128): A Phase 3, Multicenter, Randomized, Open-Label Study of Epcoritamab Plus Lenalidomide Compared to Rituximab Plus Gemcitabine and Oxaliplatin in Participants with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Grants and Contracts Details

StatusActive
Effective start/end date1/15/25 → 1/15/27

Funding

  • AbbVie Incorporated: $18,000.00